Want to see SE:FLERIE full AI Analyst Report?

InDex Pharmaceuticals Holding AB (FLERIE) Price & Analysis

2 Followers

FLERIE Stock Chart & Stats

kr18.60

-kr0.20(-0.98%)

At close: Jul 28 4:00 PM EDT

kr18.60

-kr0.20(-0.98%)

Day’s Range― - ―

52-Week Rangekr16.60 - kr37.58

Previous CloseN/A

Volume46.31K

Average Volume (3M)26.52K

Market Cap

kr1.61B

Enterprise Valuekr1.53K

Total Cash (Recent Filing)kr305.70M

Total Debt (Recent Filing)kr1.70M

Price to Earnings (P/E)―

Beta0.04

Next Earnings

Oct 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-10.56

Shares Outstanding86,697,700

10 Day Avg. Volume36,732

30 Day Avg. Volume26,523

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)0.76

Price to Sales (P/S)290.28

P/FCF Ratio-90.91

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Very Low LeverageMinimal leverage reduces refinancing and solvency risk, preserving financial flexibility while the company advances its clinical and regulatory programs. The strong capital base can provide greater capacity to absorb operating volatility than a highly indebted biotechnology business.

Focused Immunology StrategyA concentrated focus on immunology gives InDex a clear therapeutic strategy and allows scarce development resources to be directed toward a lead asset. If cobitolimod progresses successfully, this specialization could support a coherent partnering and commercialization pathway.

Asset-light Partnering ModelAn asset-light operating model limits the need to build large manufacturing and commercial infrastructure before product approval. This can keep the organization focused on clinical value creation and make partnering a scalable route to future milestone, royalty, or licensing revenue.

Bears Say

Persistent Cash BurnConsistently negative operating and free cash flow means the business is not funding its activities internally. Continued clinical development therefore depends on existing capital or future financing and partnering proceeds, creating a durable constraint on execution and financial planning.

Large Ongoing LossesLarge recurring losses show that the current operating base is far from generating sustainable returns on capital. This weak earnings profile can accelerate resource consumption, limit reinvestment from operations, and leave future financial performance highly dependent on successful development outcomes.

Unreliable Revenue GenerationHighly volatile revenue, including negative TTM revenue, provides little dependable support for ongoing costs or forecasting. Because revenue depends on clinical progress and partnering arrangements before commercialization, visibility into durable income remains weak over the coming quarters.

FLERIE FAQ

What was InDex Pharmaceuticals Holding AB’s price range in the past 12 months?

InDex Pharmaceuticals Holding AB lowest stock price was kr16.60 and its highest was kr37.58 in the past 12 months.

What is InDex Pharmaceuticals Holding AB’s market cap?

InDex Pharmaceuticals Holding AB’s market cap is kr1.61B.

When is InDex Pharmaceuticals Holding AB’s upcoming earnings report date?

InDex Pharmaceuticals Holding AB’s upcoming earnings report date is Oct 15, 2026 which is in 28 days.

How were InDex Pharmaceuticals Holding AB’s earnings last quarter?

InDex Pharmaceuticals Holding AB released its earnings results on Jul 09, 2026. The company reported -kr1.017 earnings per share for the quarter.

Is InDex Pharmaceuticals Holding AB overvalued?

According to Wall Street analysts InDex Pharmaceuticals Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does InDex Pharmaceuticals Holding AB pay dividends?

InDex Pharmaceuticals Holding AB does not currently pay dividends.

What is InDex Pharmaceuticals Holding AB’s EPS estimate?

InDex Pharmaceuticals Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does InDex Pharmaceuticals Holding AB have?

InDex Pharmaceuticals Holding AB has 86,697,700 shares outstanding.

What happened to InDex Pharmaceuticals Holding AB’s price movement after its last earnings report?

InDex Pharmaceuticals Holding AB reported an EPS of -kr1.017 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of InDex Pharmaceuticals Holding AB?

Currently, no hedge funds are holding shares in SE:FLERIE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

InDex Pharmaceuticals Holding AB

Flerie AB (publ) functions as a venture capital entity, concentrating its investments on nascent businesses. The firm actively seeks to fund biotechnology and pharmaceutical companies dedicated to advancing drug discovery and development, or producing innovative tools and applications aimed at addressing pressing global health concerns. Geographically, their investment scope includes Europe, the United States, and Israel. Founded in 2011, Flerie AB (publ) is headquartered in Stockholm, Sweden, and also operates a branch office in London, United Kingdom.